ExpreS2ion to Present in Upcoming Investor and Scientific Events
Hørsholm, Denmark, 9 January 2025 – ExpreS2ion Biotech Holding AB’s subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion") is pleased to announce its participation in two key upcoming events: PepTalk – the Annual Protein Science and Production Week in San Diego, USA, and an Institutional Investor Seminar hosted by HC Andersen Capital in Copenhagen, Denmark.
Read morePublication of clinical Phase IIb trial data for the adjuvanted RH5.1 blood-stage malaria vaccine
Hørsholm, Denmark, 11 December 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces the new publication in The Lancet Infectious Diseases titled “Safety and efficacy of the blood-stage malaria vaccine RH5.1/Matrix-M in Burkina Faso: interim results of a double-blind, randomised, controlled phase 2b trial in children”. The article is based on a…
Read moreAnalysguiden Publishes Research Report on ExpreS2ion Biotech with Price Target of SEK 91
Hørsholm, Denmark, 11 December 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") is pleased to announce that Analysguiden has published a detailed research report analysing the company’s recent progress and setting a price target of SEK 91.
Read more